Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489617 · ClinicalTrials.gov registry record · NA
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
A NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 246
- Enrollment target
- 18
- Study locations
NCT02489617 is a NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 246 participants. The trial reports 18 study locations across 9 states.
The verdict
NCT02489617, a NA study of Flat Epithelia Atypia and Intraductal Papilloma Without Atypia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 246 participants
- Enrollment target
- 18
- Study locations
Study Summary
This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle biopsy.
Conditions Studied
Interventions
- OTHER Pathologic evaluation of excised tissue
Study Locations (18)
Maryland
- MedStar Union Memorial Hospital - Baltimore
- MedStar Franklin Square Medical Center - Baltimore
- Johns Hopkins University - Baltimore
- Howard County General Hospital - Columbia
District of Columbia
- Georgetown University - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
- Sibley Memorial Hospital - Washington D.C.
North Carolina
- University of North Carolina - Chapel Hill
- Duke University - Durham
- University of North Carolina - Hillsborough Campus - Hillsborough
New Jersey
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial SLoan Kettering Bergen - Montvale
New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
Alabama
- University of Alabama at Birmingham - Birmingham
Indiana
- Indiana University - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-09 |
| Est. Completion | 2025-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02489617
The ClinicalTrials.gov registry entry for NCT02489617 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Flat Epithelia Atypia appearing as the primary indexed condition, and to 1 intervention - of which Pathologic evaluation of excised tissue is the first listed.
NCT02489617 reports 18 study locations spanning 9 distinct geographic areas - top geographies include Maryland, District of Columbia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02489617 about?
NCT02489617 is a clinical study titled "The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy". This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle biopsy.
What is the current status of trial NCT02489617?
This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2015-09. Estimated completion is 2025-06.
What conditions does trial NCT02489617 study?
This clinical trial studies the following conditions: Flat Epithelia Atypia, Intraductal Papilloma Without Atypia.
What interventions are being tested in trial NCT02489617?
The interventions under investigation include: Pathologic evaluation of excised tissue (OTHER).
Who is sponsoring clinical trial NCT02489617?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02489617 being conducted?
This trial has 18 study locations across Alabama, District of Columbia, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.